MBX MBX Bio: Company Short-Term Debts

MBX Biosciences (MBX) - corporate logo

MBX Biosciences Inc (MBX) specializes in developing treatments for endocrine pathologies. The company relies on robotic synthesis for production, although final drug verification remains with physicians. This price chart illustrates the trend of the indicator, which currently stands at 0.00. Operating within the US legal framework and the humanitarian status of its developments minimize external political risks for the business.

MBX Biosciences (MBX) - Company Short-Term Loans and Borrowings from 09/14/2024 to 10/31/2026

Analytical breakdowns and data insights for company MBX Corp (MBX)

- current quotes and average value forecast:
Price Chart MBX Biosciences|MBX - Consensus Target
- company stock capitalization data:
Market Capitalization MBX Biosciences Inc|MBX - Enterprise Value
- business book valuation details:
Accounting Value per Share MBX Biosciences|MBX - Accounting Value of Company|Market Value to Book Value Ratio mbxbio.com|MBX - Cumulative Company Assets
- debt level and financial liquidity data:
Total Debt to Capital MBX Biosciences Inc|MBX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio MBX Biosciences Inc|MBX - Company Cumulative Indebtedness|Debts to Book Capitalization MBX Biosciences Inc|MBX - Company Long-Term Debts|Company Short-Term Debts MBX Biosciences|Quick Liquidity mbxbio.com
- earnings and valuation multiples indicators:
MBX - Company Net Income
Summary company analytics:MBX Biosciences (MBX)
Manufactured products of mbxbio.com

Stress testing assets requires assessing the issuer's resilience to sudden financial shocks. MBX Biosciences Inc (MBX) operates in a high capital expenditure mode without current revenue. Analyzing loans maturing within one year through changes in short-term liabilities reveals the risk of cash flow gaps. This metric measures liquidity, which is critical during drug development. Rising debt amid stage-specific risks increases the business's vulnerability.

Competitors of MBX Biosciences Inc (MBX)

ASND - Company Short-Term Debt|Madrigal Pharmaceuticals Inc (MDGL) - Company Current Liabilities|CORT: Company Short-Term Debts|Rhythm Corp (RYTM) - Company Short-Term Debts|Company Current Liabilities AKRO|MTSR: Company Short-Term Loans and Borrowings|Company Short-Term Debt MoonLake (MLTX)|Company Current Liabilities Crinetics Pharmaceuticals, Inc. CRNX|Company Short-Term Debts NAMS (NewAmsterdam Pharma N.V.)|Soleno Therapeutics Corp (SLNO) - Short-Term Debt|FOLD: Company Current Liabilities|89bio.com - Amount of Current Liabilities|AGIO: Company Short-Term Debts|Structure Therapeutics Inc (GPCR) - Company Short-Term Debts|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debt RZLT|Company Short-Term Debt Lexicon Pharmaceuticals (LXRX)|ALT - Short-Term Debt|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Company Short-Term Debt|BioAge Labs Inc. - Company Short-Term Debts|Short-Term Debt Volume Biomea Fusion Corp BMEA|quincetx.com (QNCX) - Company Short-Term Debt|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Company Current Liabilities Agape ATP Corp. (ATPC)|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|Matinas BioPharma Holdings, Inc. - Company Short-Term Debt|SPRB: Company Current Liabilities|GLTO (Galecto Inc) - Company Short-Term Indebtedness|CTCX (Carmell Corp) - Company Current Liabilities|Lumos Therapeutics - Company Short-Term Loans and Borrowings|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|Company Short-Term Debt RDUS